US green light for Pfizer/Merck diabetes therapies
Pfizer and Merck’s diabetes drugs Steglatro and Steglujan have been approved for the US market.
Read More
Tag: sitagliptin
FDA rejects CV outcomes claim for Merck diabetes drugs
The US Food and Drug Administration has dealt Merck & Co a blow in turning down its request to have cardiovascular outcomes data added to the labels of its diabetes drugs Januvia and Janumet.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
